Oncologic therapy related adverse events: Difference between revisions
Ostermayer (talk | contribs) (Created page with "==Background== ==Clinical Features== *Many novel oncologic therapies and Biologic immunomodulators adverse reactions may mimic common ED presentations such as sepsis. ==...") |
Ostermayer (talk | contribs) |
||
| Line 26: | Line 26: | ||
==See Also== | ==See Also== | ||
*[[Biologic immunomodulators]] | *[[Biologic immunomodulators]] | ||
==External Links== | ==External Links== | ||
Revision as of 17:37, 4 March 2020
Background
Clinical Features
- Many novel oncologic therapies and Biologic immunomodulators adverse reactions may mimic common ED presentations such as sepsis.
Types of novel oncologic agents
- Genetically engineered T cells
- CD19–chimeric antigen receptor (CAR)-T cell therapy
- Monoclonal Antibodies against PD-1 checkpoints
- Small-molecule inhibitors
- Antibody-drug conjugates
- Immunotoxins
- Bispecific T-cell engagers
Differential Diagnosis
- Decreased cellular immunity which an cause reactivation or new
- Neurologic syndromes
- Hematologic side effects
- Cardiac effects
- Allergic reactions
- Pulmonary
- Endocrine
- GI
- Perforations
- Clostridium difficile
- Acute bacterial infections
- Malignancies
- Non-melanoma skin cancers
- Lymphoma